Invitae joins NIH-sponsored study aimed at improving understanding of the links between genes and cancer, heart disease and other conditions
Excerpt from the Press Release:
SAN FRANCISCO, April 8, 2021 /PRNewswire/ — Invitae Corporation (NYSE: NVTA), a leading medical genetics company, has joined eMERGE Network, a nationwide effort organized and funded by the National Human Genome Research Institute (NHGRI) that connects genetic data and electronic medical record (EMR) systems to advance the use of genetics in healthcare. As a new clinical affiliate, Invitae will provide genetic testing for a study of up to 25,000 patients to evaluate the impact of population screening.
“Our own research has shown that people can harbor a genetic change that could put them at increased risk for conditions like cancer and heart disease. The eMERGE study is part of the work conducted by the NHGRI to improve understanding of these rates in diverse populations, with an emphasis on underrepresented minorities, and identify best practices for population screening,” said Robert Nussbaum, M.D., chief medical officer at Invitae. “We’re proud to be participating in this important effort, through which we hope to not only help provide information that study participants can use to improve their health but also contribute important findings that may improve healthcare for all.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?